- Cancer treatment specialist Kazia Therapeutics (KZA) is teaming up with the U.S. Dana-Farber Cancer Institute (DFCI) to treat a rare type of lymphoma
- Kazia’s paxlisib drug will tested against primary central nervous system lymphoma (PCNSL), which is a specific type of cancer of the white blood cells
- The trial will also recruit up to 25 patients who have relapsed or refractory PCNSL
- Recruitment for the trial is slated for early 2021, and it’s expected to take two years to complete
- The Dana-Farber Cancer Institute is a principal teaching affiliate of Harvard Medical School
- Shares in Kazia rose in early action but have since settled and are currently trading grey, worth 94 cents each
